KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial.

Marc-Andrea Baertsch, Jana Schlenzka, Thomas Hielscher, Marc S Raab, Sandra Sauer, Maximilian Merz, Elias Karl Mai, Carsten Müller-Tidow, Steffen Luntz, Anna Jauch, Peter Brossart, Martin Goerner, Stefan Klein, Bertram Glass, Peter Reimer, Ullrich Graeven, Roland Fenk, Mathias Haenel, Ivana von Metzler, Hans W Lindemann, Christof Scheid, Igor-Wolfgang Blau, Hans J Salwender, Richard Noppeney, Britta Besemer, Katja C Weisel, Hartmut Goldschmidt

Blood 145(16) 1780-1787

PMID39808798
PMCIDPMC12060157
DOI10.1182/blood.2024027342
发表日期2025-01-14
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 1.:森林图/亚组分析图;Figure 2.:森林图/亚组分析图。
摘要

摘要

The multicenter, phase 3 German-Speaking Myeloma Multicenter Group (GMMG) ReLApsE trial randomized patients with relapsed and/or refractory multiple myeloma (RRMM) equally to lenalidomide/dexamethasone (LEN/DEX; 25 mg days 1-21, DEX 40 mg weekly, in 4-week cycles) reinduction, salvage high-dose chemotherapy (sHDCT; melphalan 200 mg/m2), autologous stem cell transplantation (ASCT), and LEN maintenance (10 mg/d; transplant arm, n = 139) vs continuous LEN/DEX (control arm, n = 138). Ninety-four percent of patients had received frontline HDCT/ASCT. We report an updated analysis of survival end points with a median follow-up of 99 months. Median progression-free survival (PFS) was 20.5 and 19.3 months in the transplant and control arm, respectively (hazard ratio [HR], 0.98; P = .9). Median overall survival (OS) was 67.1 and 62.7 months, respectively, (HR 0.89; P = .44). Landmark analyses from sHDCT and the contemporaneous LEN/DEX cycle 5 were performed because of 29% dropout of patients before sHDCT/ASCT in the transplant arm but did not reveal significant differences in PFS/OS. Time to progression after frontline HDCT/ASCT was a prognostic factor but did not predict benefit from sHDCT/ASCT. The GMMG ReLApsE trial does not support use of sHDCT/ASCT in RRMM after frontline HDCT/ASCT. This trial was registered at www.clinicaltrialsregister.eu as #EudraCT2009-013856-61.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1无图注
非 KM Figure
Figure 1.PFS and OS from randomization. Kaplan-Meier curves of PFS and OS in the intention-to-treat population by trial arm (A) and by TTP1 (B), as well as in the subgroup with TTP1 of >48 months by trial arm (C).
非 KM Figure
Figure 2.PFS and OS from the landmark at HDCT/ASCT and LEN/DEX cycle 5. PFS and OS from the landmark by trial arm as Kaplan-Meier curves in all patients that reached the landmark (A) and in the subgroup of patients with TTP1 of >48 months (B).
非 KM Figure